Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

May 10, 2024

Study Completion Date

May 10, 2024

Conditions
Post-COVID-19 Syndrome
Interventions
DRUG

Temelimab 54mg/kg

Temelimab 54mg/kg will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)

DRUG

Placebo

Placebo will be given as monthly (every 4 weeks) intravenous (IV) infusion over 24 weeks (6 infusions in total)

Trial Locations (14)

301

Inselspital Bern University Hospital Bern, Bern

1211

Geneva University Hospital, Geneva

1951

Centre hospitalier du Valais Romand (CHVR) - Hôpital du Valais, Sion

4055

REHAB Clinic for Neurorehabilitation and Paraplegiology, Basel

7000

Kantonsspital Graubünden, Chur

28036

Private clinic Blue Healthcare, Madrid

28223

Hospital Universitario Quirónsalud Madrid, Madrid

39049

Hospital of Vipiteno, Sterzing

41124

Clinica Metabolica dell'Università di Modena e Reggio Emilia, Modena

46014

Hospital General Universitario- Servicio de Medicina Interna, Valencia

50015

Hospital Royo Villanova, Zaragoza

00133

U.O.C. Malattie Infettive Tor Vergata, Policlincio Tor Vergata, Roma

00168

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

08028

Ace Alzheimer Center, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GeNeuro SA

INDUSTRY

NCT05497089 - Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome | Biotech Hunter | Biotech Hunter